Multiple Sclerosis News Today

January 17, 2022January 17, 2022

‘No Surprises Act’ Aims to Rein In Out-of-network Billing in US

Multiple Sclerosis News Today

Under rules in the No Surprises Act, insured patients people in the U.S., including those with multiple sclerosis, should no longer receive unexpected medical bills for emergency care or for ... Read more

January 17, 2022January 17, 2022

1st RRMS Patient Enrolled in ENSURE-2 Trial of Oral IMU-838

Multiple Sclerosis News Today

The ENSURE-2 Phase 3 clinical trial, evaluating Immunic Therapeutics’ experimental oral therapy IMU-838 (vidofludimus calcium) in adults with relapsing-remitting multiple sclerosis (RRMS), has enrolled its first patient. The milestone, announced ... Read more

January 14, 2022January 15, 2022

Epstein-Barr Virus May be Leading Cause of MS, Raising Risk by 32 Times

Multiple Sclerosis News Today

Infection with the common Epstein-Barr virus (EBV) increases the risk of developing multiple sclerosis (MS) by 32 times — the strongest link yet — according to a study looking at two ... Read more

January 14, 2022January 14, 2022

Trial of Cannabidiol-derived EHP-101 for Relapsing MS Enrolling Soon

Multiple Sclerosis News Today

Emerald Health Pharmaceuticals will soon begin enrollment in a Phase 2a clinical trial investigating its cannabidiol-derived therapy EHP-101 in relapsing forms of multiple sclerosis (MS). The trial (NCT04909502) aims to ... Read more

January 13, 2022January 13, 2022

MS Type, Anti-CD20 Therapies Tied to Higher COVID-19 Mortality Risk

COVID-19 News, Multiple Sclerosis News Today

A new meta-analysis revealed that, among multiple sclerosis (MS) patients, age, disease type, co-existing conditions, and the use of anti-CD20 therapies — such as ocrelizumab and rituximab — were associated ... Read more

January 13, 2022January 13, 2022

Atara, Imeka Team Up to Bring Advanced Imaging to ATA188 Trial

Multiple Sclerosis News Today

Atara Biotherapeutics has partnered with Imeka to use its proprietary biomarker imaging technology in the ongoing EMBOLD Phase 2 clinical trial, which is investigating ATA188 for the treatment of progressive ... Read more

January 12, 2022January 12, 2022

MS Patients at Increased Risk of Cancer, Perhaps Because of Lifestyle

Multiple Sclerosis News Today

People with multiple sclerosis (MS) are at greater risk of developing cancer than the general population, according to a French study involving over 100,000 patients. This increased risk was particularly ... Read more

January 12, 2022January 12, 2022

Cognitive Dysfunction Found to Increase Risk of Death in MS

Multiple Sclerosis News Today

Cognitive dysfunction in patients with multiple sclerosis (MS) is predictive of worse outcomes, including clinical progression of the disease and a higher risk of mortality, according to a new study. ... Read more

January 11, 2022January 11, 2022

2nd Patient to Get Foralumab Nasal Spray After Promising First Data

Multiple Sclerosis News Today

Following promising data from the first participant in a special access program that’s testing foralumab nasal spray for secondary progressive multiple sclerosis (SPMS), a second patient has been enrolled in the ongoing evaluation. ... Read more

January 11, 2022January 11, 2022

High Levels of Gut Bacterial Toxins Found in Spinal Fluid of MS Patients

Multiple Sclerosis News Today

People with multiple sclerosis (MS) have high levels of toxic compounds made by gut bacteria in the fluid around their brain and spinal cord, a study found. “This work not ... Read more

January 10, 2022January 10, 2022

FDA Expands MRI Compatibility With Spinal Stimulation for Pain

Multiple Sclerosis News Today

The U.S. Food and Drug Administration (FDA) has approved Abbott’s request to expand the magnetic resonance imaging (MRI) compatibility with its Proclaim XR spinal cord stimulation system with Octrode leads, ... Read more

January 10, 2022January 10, 2022

After Tysabri, Ocrevus Seen as Better Than Gilenya at Preventing Relapse

COVID-19 News, Multiple Sclerosis News Today

Ocrevus (ocrelizumab) may be more effective than Gilenya (fingolimod) at preventing relapse in relapsing-remitting multiple sclerosis (RRMS) patients who recently transitioned from Tysabri (natalizumab), according to a new study. Ocrevus ... Read more

January 7, 2022January 7, 2022

Phase 1 Trial of ANK-700 for RRMS Advancing to Multiple Doses

Multiple Sclerosis News Today

A Phase 1 clinical trial investigating the safety and tolerability of Anokion‘s ANK-700 in people with relapsing-remitting multiple sclerosis (RRMS) has begun enrolling patients for its multiple ascending dose part. This opening ... Read more

January 6, 2022January 6, 2022

Generics of Gilenya Not Likely in US for at Least Another Two Years

Multiple Sclerosis News Today

A decision by the U.S. Court of Appeals for the Federal Circuit has upheld the validity of a patent for dosing Novartis’ oral multiple sclerosis (MS) treatment Gilenya (fingolimod), the ... Read more

January 6, 2022January 6, 2022

New Machine Learning Algorithm Could Help in Diagnosing MS Sooner

Multiple Sclerosis News Today

A new machine learning algorithm — designed to analyze healthcare records — could help in diagnosing multiple sclerosis (MS) sooner by identifying patients’ symptoms earlier. The algorithm, devised by scientists ... Read more